Advertisement
Screener

KYNTRA BIO, INC. (KYNB) Debt Securities, Available-for-sale, Unrealized Loss Position

1.8 / 5 stars · 34/94 Roast Me

KYNTRA BIO, INC. Debt Securities, Available-for-sale, Unrealized Loss Position

KYNTRA BIO, INC. (KYNB) had Debt Securities, Available-for-sale, Unrealized Loss Position of $40.33 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position

us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-13

  • 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $40.33M.
  • 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $47.70M.
  • 2024-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $17.90M.
  • 2023-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $13.47M.
Period endDebt Securities, Available-for-sale, Unrealized Loss Position
2026-06-30$40.33M
10-Q · filed 2026-08-13
2026-03-31$47.70M
10-Q · filed 2026-05-12
2024-03-31$17.90M
10-Q · filed 2024-05-06
2023-12-31$13.47M
10-K · filed 2025-03-17
2023-09-30$41.71M
10-Q · filed 2023-11-06
2023-06-30$65.87M
10-Q · filed 2023-08-07
2023-03-31$98.86M
10-Q · filed 2023-05-08
2022-12-31$191.16M
10-K · filed 2024-02-26
2022-09-30$224.33M
10-Q · filed 2022-11-07
2021-12-31$328.16M
10-K · filed 2023-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
NextCure, Inc. (NXTC)United States$0.024B-0.15
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13